Cargando…

Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients

Introduction: Lung cancer is the deadliest and most prevalent cancer worldwide. Lung cancer treatments have different characteristics and are associated with a range of benefits and side effects for patients. Such differences may raise uncertainty among drug developers, regulators, payers, and clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Durosini, Ilaria, Janssens, Rosanne, Arnou, Reinhard, Veldwijk, Jorien, Smith, Meredith Y., Monzani, Dario, Smith, Ian, Galli, Giulia, Garassino, Marina, Katz, Eva G., Bailo, Luca, Louis, Evelyne, Vandevelde, Marie, Nackaerts, Kristiaan, de Wit, G. Ardine, Pravettoni, Gabriella, Huys, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900128/
https://www.ncbi.nlm.nih.gov/pubmed/33634069
http://dx.doi.org/10.3389/fpubh.2021.622154
_version_ 1783654157087932416
author Durosini, Ilaria
Janssens, Rosanne
Arnou, Reinhard
Veldwijk, Jorien
Smith, Meredith Y.
Monzani, Dario
Smith, Ian
Galli, Giulia
Garassino, Marina
Katz, Eva G.
Bailo, Luca
Louis, Evelyne
Vandevelde, Marie
Nackaerts, Kristiaan
de Wit, G. Ardine
Pravettoni, Gabriella
Huys, Isabelle
author_facet Durosini, Ilaria
Janssens, Rosanne
Arnou, Reinhard
Veldwijk, Jorien
Smith, Meredith Y.
Monzani, Dario
Smith, Ian
Galli, Giulia
Garassino, Marina
Katz, Eva G.
Bailo, Luca
Louis, Evelyne
Vandevelde, Marie
Nackaerts, Kristiaan
de Wit, G. Ardine
Pravettoni, Gabriella
Huys, Isabelle
author_sort Durosini, Ilaria
collection PubMed
description Introduction: Lung cancer is the deadliest and most prevalent cancer worldwide. Lung cancer treatments have different characteristics and are associated with a range of benefits and side effects for patients. Such differences may raise uncertainty among drug developers, regulators, payers, and clinicians regarding the value of these treatment effects to patients. The value of conducting patient preference studies (using qualitative and/or quantitative methods) for benefits and side effects of different treatment options has been recognized by healthcare stakeholders, such as drug developers, regulators, health technology assessment bodies, and clinicians. However, evidence-based guidelines on how and when to conduct and use these studies in drug decision-making are lacking. As part of the Innovative Medicines Initiative PREFER project, we developed a protocol for a qualitative study that aims to understand which treatment characteristics are most important to lung cancer patients and to develop attributes and levels for inclusion in a subsequent quantitative preference survey. Methods: The study protocol specifies a four-phased approach: (i) a scoping literature review of published literature, (ii) four focus group discussions with stage III and IV Non-Small Cell Lung Cancer patients, (iii) two nominal group discussions with stage III and IV Non-Small Cell Lung Cancer patients, and (iv) multi-stakeholder discussions involving clinicians and preference experts. Discussion: This protocol outlines methodological and practical steps as to how qualitative research can be applied to identify and develop attributes and levels for inclusion in patient preference studies aiming to inform decisions across the drug life cycle. The results of this study are intended to inform a subsequent quantitative preference survey that assesses patient trade-offs regarding lung cancer treatment options. This protocol may assist researchers, drug developers, and decision-makers in designing qualitative studies to understand which treatment aspects are most valued by patients in drug development, regulation, and reimbursement.
format Online
Article
Text
id pubmed-7900128
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79001282021-02-24 Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients Durosini, Ilaria Janssens, Rosanne Arnou, Reinhard Veldwijk, Jorien Smith, Meredith Y. Monzani, Dario Smith, Ian Galli, Giulia Garassino, Marina Katz, Eva G. Bailo, Luca Louis, Evelyne Vandevelde, Marie Nackaerts, Kristiaan de Wit, G. Ardine Pravettoni, Gabriella Huys, Isabelle Front Public Health Public Health Introduction: Lung cancer is the deadliest and most prevalent cancer worldwide. Lung cancer treatments have different characteristics and are associated with a range of benefits and side effects for patients. Such differences may raise uncertainty among drug developers, regulators, payers, and clinicians regarding the value of these treatment effects to patients. The value of conducting patient preference studies (using qualitative and/or quantitative methods) for benefits and side effects of different treatment options has been recognized by healthcare stakeholders, such as drug developers, regulators, health technology assessment bodies, and clinicians. However, evidence-based guidelines on how and when to conduct and use these studies in drug decision-making are lacking. As part of the Innovative Medicines Initiative PREFER project, we developed a protocol for a qualitative study that aims to understand which treatment characteristics are most important to lung cancer patients and to develop attributes and levels for inclusion in a subsequent quantitative preference survey. Methods: The study protocol specifies a four-phased approach: (i) a scoping literature review of published literature, (ii) four focus group discussions with stage III and IV Non-Small Cell Lung Cancer patients, (iii) two nominal group discussions with stage III and IV Non-Small Cell Lung Cancer patients, and (iv) multi-stakeholder discussions involving clinicians and preference experts. Discussion: This protocol outlines methodological and practical steps as to how qualitative research can be applied to identify and develop attributes and levels for inclusion in patient preference studies aiming to inform decisions across the drug life cycle. The results of this study are intended to inform a subsequent quantitative preference survey that assesses patient trade-offs regarding lung cancer treatment options. This protocol may assist researchers, drug developers, and decision-makers in designing qualitative studies to understand which treatment aspects are most valued by patients in drug development, regulation, and reimbursement. Frontiers Media S.A. 2021-02-05 /pmc/articles/PMC7900128/ /pubmed/33634069 http://dx.doi.org/10.3389/fpubh.2021.622154 Text en Copyright © 2021 Durosini, Janssens, Arnou, Veldwijk, Smith, Monzani, Smith, Galli, Garassino, Katz, Bailo, Louis, Vandevelde, Nackaerts, de Wit, Pravettoni and Huys. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Durosini, Ilaria
Janssens, Rosanne
Arnou, Reinhard
Veldwijk, Jorien
Smith, Meredith Y.
Monzani, Dario
Smith, Ian
Galli, Giulia
Garassino, Marina
Katz, Eva G.
Bailo, Luca
Louis, Evelyne
Vandevelde, Marie
Nackaerts, Kristiaan
de Wit, G. Ardine
Pravettoni, Gabriella
Huys, Isabelle
Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients
title Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients
title_full Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients
title_fullStr Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients
title_full_unstemmed Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients
title_short Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients
title_sort patient preferences for lung cancer treatment: a qualitative study protocol among advanced lung cancer patients
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900128/
https://www.ncbi.nlm.nih.gov/pubmed/33634069
http://dx.doi.org/10.3389/fpubh.2021.622154
work_keys_str_mv AT durosiniilaria patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT janssensrosanne patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT arnoureinhard patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT veldwijkjorien patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT smithmeredithy patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT monzanidario patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT smithian patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT galligiulia patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT garassinomarina patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT katzevag patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT bailoluca patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT louisevelyne patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT vandeveldemarie patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT nackaertskristiaan patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT dewitgardine patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT pravettonigabriella patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients
AT huysisabelle patientpreferencesforlungcancertreatmentaqualitativestudyprotocolamongadvancedlungcancerpatients